GlassScriptPhysician profile
Lyndsie Thompson
NPI 1306215017
$6,351.39
in general payments reported to CMS, 2019-2025
22 companies · $2,662 in 2025
The $2,662 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $53.06 · 2022: $315 · 2023: $1,139 · 2024: $2,183 · 2025: $2,662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,703 · Education: $281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,702.92 |
| Education | $280.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,198.98 | 2023-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $903.00 | 2024-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $745.85 | 2023-2025 | |
| Abbvie INC. | $724.26 | 2023-2025 | |
| Janssen Biotech, INC. | $609.37 | 2023-2025 | Tremfya, Simponi, Stelara |
| Merz North America, INC. | $373.65 | 2022-2023 | Xeomin |
| Genzyme Corporation | $348.50 | 2023-2025 | |
| Galderma Laboratories, L.P. | $339.78 | 2021-2025 | Nemluvio, Aklief |
| Leo Pharma INC. | $241.19 | 2024-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $205.89 | 2024-2025 | |
| Dermavant Sciences, INC. | $185.39 | 2023-2024 | Vtama |
| Organon LLC | $92.67 | 2025 | Nexplanon |
| Regeneron Healthcare Solutions, INC. | $88.45 | 2023-2024 | Dupixent |
| Pfizer INC. | $75.15 | 2023-2025 | |
| Lilly USA, LLC | $59.42 | 2024-2025 | Ebglyss, Taltz |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $37.66 | 2025 | Sotyktu |
| Allergan, INC. | $33.38 | 2022 | |
| Journey Medical Corporation | $25.74 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $22.09 | 2021 | |
| Botanix Sb INC | $14.60 | 2025 | Sofdra |
| Amgen INC. | $13.73 | 2024 | Otezla |
| Welch Allyn | $12.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lyndsie Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.